← TrialMatch
HomeTrials

First Responder Airway & Compression Rate Trial

The First responder Airway \& Compression rate Trial (FACT) Study will address basic life support (BLS) treatments administered by Emergency Medical Services (EMS) first responders to patients who suffer a sudden circulatory (pulseless) collapse, referred to as sudden out-of-hospital cardiac arrest (SCA). The investiga

Condition(s)Out-Of-Hospital Cardiac Arrest
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe First responder Airway \& Compression rate Trial (FACT) Study will address basic life support (BLS) treatments administered by Emergency Medical Services (EMS) first responders to patients who suffer a sudden circulatory (pulseless) collapse, referred to as sudden out-of-hospital cardiac arrest (SCA). The investigators propose a randomized controlled trial among persons who suffer SCA to compare these two rescue breathing approaches (standard Bag Valve Mask vs i-gel) along with evaluating a more precise chest compression rate within the range of 100-120 compressions per minute during CPR. Importantly, each of these treatments fall within established resuscitation guidelines and are already administered as part of standard care in clinical practice. Thus this proposed trial will essenti
Who can participateInclusion Criteria: * Adults suffering out-of-hospital non-traumatic SCA in Seattle and greater King County in whom resuscitation will be attempted by first responding EMS personnel. Exclusion Criteria: * if advanced paramedic providers are first on-scene and have already initiated advanced life support (ALS) procedures, * a written advance directive (do not attempt resuscitation orders), * traumatic arrest (blunt, penetrating, burn), * known prisoner, * known pregnancy, * other protected populations (pediatrics), * pre-existing tracheostomy, * recipients of mechanical ventilator support, or * presence of an "opt out" bracelet to not be enrolled in clinical trials.
Ages18 Years
SexAll
Lead sponsorUniversity of Washington
LocationsSeattle, Washington, United States
Start date2024-02-07
NCT IDNCT05969028
Official listinghttps://clinicaltrials.gov/study/NCT05969028

🔍 Search all trials →